P2D Bioscience

Employee Size

2-10

Organization Type

Privately Held

Headquarters

Cincinnati, OH

Founded

2005

P2D Bioscience is a specialty pharmaceutical company developing drug candidates for inflammatory disorders of the central nervous system, with a pipeline aimed at frontotemporal dementia, Alzheimer’s disease and ADHD. Its approach combines targeted phenotypic screening with transgenic preclinical models, while its management brings deep experience in neuroscience, toxicology and early-stage drug development. The company advances candidates through preclinical and early clinical studies before seeking partners for later development and commercialization.

• Gilgamesh PharmaGilgamesh Pharma is a New York clinical-stage neuroscience biotech developing novel chemical entities for psychiatric disease, with an emphasis on rapid-acting and durable therapies rather than symptom management alone. Its in-house discovery platform combines medicinal chemistry, neurocircuitry science, and computational modeling, and has produced clinical programs including blixeprodil and a neuroplastogen partnership with AbbVie. The company’s first clinical asset, bretisilocin, was acquired by AbbVie after advancing to Phase 2.New York, NY
• Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA
• Neuropathix, IncFounded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.DOYLESTOWN, PA
• NeuroNascent, IncFounded by neuroscientist Judith Kelleher-Andersson, NeuroNascent is a privately held biotechnology company developing oral small-molecule therapies designed to stimulate the brain’s own neuron regeneration. Its lead candidate, NNI-362, has completed Phase 1a safety testing in healthy older adults and is being advanced for Alzheimer’s and Parkinson’s disease, while the company’s patented discovery platform also supports programs in other neurological disorders. The Clarksville, Maryland company is led by a team with deep experience in central nervous system drug development.CLARKSVILLE, MD